This file is part of IDEAS, which uses RePEc data

Wolters Kluwer Health | Adis

PharmacoEconomics

Contact information of Wolters Kluwer Health | Adis:
Web page: http://pharmacoeconomics.adisonline.com/

To be notified about new items in this series: Register for eTOC http://pharmacoeconomics.adisonline.com/pt/re/phe/etocs.htm (see also NEP)
Download restrictions: Pay per view
Editor:
For technical questions regarding this series, please contact (Remco Bouckaert)
Series handle: repec:wkh:phecon

More pages of listings: 0|1|2|3|4|5

2008, Volume 26, Issue 10

807-809 Trastuzumab in Early-Stage Breast Cancer: The Question of Treatment Timing
by Steven Simoens [Downloadable! (restricted)]
811-814 Funding a Clinical Trial: The Perspective of a Medicines Funder
by Peter Alsop & Scott Metcalfe & Jackie Evans [Downloadable! (restricted)]
815-830 Unrelated Medical Costs in Life-Years Gained: Should They be Included in Economic Evaluations of Healthcare Interventions?
by David R. Rappange & Pieter H.M. van Baal & N. Job A. van Exel & Talitha L. Feenstra & Frans F.H. Rutten & Werner B.F. Brouwer [Downloadable! (restricted)]
831-846 Quality-of-Life Assessment in Rheumatoid Arthritis
by Anthony S. Russell [Downloadable! (restricted)]
847-860 Multiple Sclerosis in the UK: Service Use, Costs, Quality of Life and Disability
by Paul McCrone & Margaret Heslin & Martin Knapp & Paul Bull & Alan Thompson [Downloadable! (restricted)]
861-877 Costs and Effects of Secondary Prevention with Perindopril in Stable Coronary Heart Disease in Poland: An Analysis of the EUROPA Study Including 1251 Polish Patients
by W. Ken Redekop & Ewa Orlewska & Pawel Maciejewski & Frans F.H. Rutten & Louis W. Niessen [Downloadable! (restricted)]
879-889 Long-Term Cost-Effectiveness Analysis of Nebivolol Compared with Standard Care in Elderly Patients with Heart Failure: An Individual Patient-Based Simulation Model
by Guiqing Yao & Nick Freemantle & Marcus Flather & Puvan Tharmanathan & Andrew Coats & Philip A. Poole-Wilson [Downloadable! (restricted)]
891-892 Assessing the Value of a Future Study
by Afschin Gandjour [Downloadable! (restricted)]
892-894 The Authors' Reply
by Oren Shavit & Moshe Leshno & Assaf Goldberger & Amir Shmueli & Amnon Hoffman [Downloadable! (restricted)]

2008, Volume 26, Issue 9

721-724 NICE's 2008 Methods Guide: Sensible Consolidation or Opportunities Missed?
by Mark Sculpher [Downloadable! (restricted)]
725-727 NICE Guide to the Methods of Technology Appraisal: Pharmaceutical Industry Perspective
by Julia Earnshaw & Gavin Lewis [Downloadable! (restricted)]
729-732 NICE Methodology for Technology Appraisals: Cutting Edge or Tried and Trusted?
by Louise Longworth & Carole Longson [Downloadable! (restricted)]
733-744 The NICE Cost-Effectiveness Threshold: What it is and What that Means
by Christopher McCabe & Karl Claxton & Anthony J. Culyer [Downloadable! (restricted)]
745-751 Estimating `Costs' for Cost-Effectiveness Analysis
by Alec Miners [Downloadable! (restricted)]
753-767 Use of Indirect and Mixed Treatment Comparisons for Technology Assessment
by Alex Sutton & A.E. Ades & Nicola Cooper & Keith Abrams [Downloadable! (restricted)]
769-779 Valuing Health States for Use in Cost-Effectiveness Analysis
by John Brazier [Downloadable! (restricted)]
781-798 Exploring Uncertainty in Cost-Effectiveness Analysis
by Karl Claxton [Downloadable! (restricted)]
799-806 Subgroups and Heterogeneity in Cost-Effectiveness Analysis
by Mark Sculpher [Downloadable! (restricted)]

2008, Volume 26, Issue 8

629-632 Waiting for Reimbursement of New Medicines in Canada: It's Time for a Rethink
by Brett J. Skinner [Downloadable! (restricted)]
633-648 Modelling Approaches: The Case of Schizophrenia
by Bart M.S. Heeg & Joep Damen & Erik Buskens & Sue Caleo & Frank de Charro & Ben A. van Hout [Downloadable! (restricted)]
649-659 Assessing the Impact of Global Price Interdependencies
by Anke Richter [Downloadable! (restricted)]
661-677 Conducting Discrete Choice Experiments to Inform Healthcare Decision Making: A User's Guide
by Emily Lancsar & Jordan Louviere [Downloadable! (restricted)]
679-697 Demand Forecasting for Preventive AIDS Vaccines: Economic and Policy Dimensions
by Robert Hecht & Gian Gandhi [Downloadable! (restricted)]
699-719 Trastuzumab: A Pharmacoeconomic Review of its Use in Early Breast Cancer
by Kate McKeage & Katherine A. Lyseng-Williamson [Downloadable! (restricted)]

2008, Volume 26, Issue 7

537-550 Recent National and Regional Drug Reforms in Sweden: Implications for Pharmaceutical Companies in Europe
by Bjorn Wettermark & Brian Godman & Karolina Andersson & Lars L. Gustafsson & Alan Haycox & Vittorio Bertele' [Downloadable! (restricted)]
551-556 Pharmaceutical Risk-Sharing Agreements
by Joseph P. Cook & John A. Vernon & Richard Manning [Downloadable! (restricted)]
557-566 Does Direct-to-Consumer Advertising of Antidepressants Lead to a Net Social Benefit?
by Jon Jureidini & Barbara Mintzes & Melissa Raven [Downloadable! (restricted)]
567-568 The Author's Reply
by Adam E. Block [Downloadable! (restricted)]
569-587 Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes: A Systematic Review on Content and Adherence to Guidelines
by Stefan Vegter & Cornelis Boersma & Mark Rozenbaum & Bob Wilffert & GerJan Navis & Maarten J. Postma [Downloadable! (restricted)]
589-602 Future Drug Prices and Cost-Effectiveness Analyses
by Martin Hoyle [Downloadable! (restricted)]
603-616 Generic Entry, Reformulations and Promotion of SSRIs in the US
by Haiden A. Huskamp & Julie M. Donohue & Catherine Koss & Ernst R. Berndt & Richard G. Frank [Downloadable! (restricted)]
617-627 Cost-Effectiveness Analyses of Natalizumab (Tysabri(R)) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
by Ray Gani & Gavin Giovannoni & David Bates & Belinda Kemball & Steve Hughes & John Kerrigan [Downloadable! (restricted)]

2008, Volume 26, Issue 6

447-462 Economic Burden of Heart Failure in the Elderly
by Lawrence Liao & Larry A. Allen & David J. Whellan [Downloadable! (restricted)]
463-476 Cost of Epilepsy: A Systematic Review
by Adam Strzelczyk & Jens Peter Reese & Richard Dodel & Hajo M. Hamer [Downloadable! (restricted)]
477-495 Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada
by Deborah A. Marshall & Patrick R. Douglas & Michael F. Drummond & George W. Torrance & Stuart MacLeod & Orlando Manti & Lokanadha Cheruvu & Ron Corvari [Downloadable! (restricted)]
497-511 Cost-Utility Analysis of Varenicline versus Existing Smoking Cessation Strategies using the BENESCO Simulation Model: Application to a Population of US Adult Smokers
by Paul Howard & Christopher Knight & Annabel Boler & Christine Baker [Downloadable! (restricted)]
513-536 Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis
by Dirk Mueller & Eva Weyler & Afschin Gandjour [Downloadable! (restricted)]

2008, Volume 26, Issue 5

359-361 Cost-Effectiveness Analysis: Developing Nations Left Behind
by Mendel E. Singer [Downloadable! (restricted)]
363-370 Perspectives on Patient-Reported Outcomes: Content Validity and Qualitative Research in a Changing Clinical Trial Environment
by Nancy Kline Leidy & Margaret Vernon [Downloadable! (restricted)]
371-393 Economic Evaluation of Interventions to Treat Opiate Dependence: A Review of the Evidence
by Christopher M. Doran [Downloadable! (restricted)]
395-408 Economic Evaluations in Rheumatoid Arthritis: A Critical Review of Measures Used to Define Health States
by Nick Bansback & Roberta Ara & Jonathan Karnon & Aslam Anis [Downloadable! (restricted)]
409-423 Methodological Issues in Evaluating Cost Effectiveness of Adjuvant Aromatase Inhibitors in Early Breast Cancer: A Need for Improved Modelling to Aid Decision Making
by Lieven Annemans [Downloadable! (restricted)]
425-434 A Multicentre, Prospective Study to Evaluate Costs of Septic Patients in Brazilian Intensive Care Units
by Ana M.C. Sogayar & Flavia R. Machado & Alvaro Rea-Neto & Amselmo Dornas & Cintia M.C. Grion & Suzana M.A. Lobo & Bernardo R. Tura & Carla L.O. Silva & Ruy G.R. Cal & Idal Beer & Vilto Michels & Jorge Safi & Marcia Kayath & Eliezer Silva [Downloadable! (restricted)]
435-446 Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-alpha Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia
by Shelby D. Reed & Kevin J. Anstrom & Yanhong Li & Kevin A. Schulman [Downloadable! (restricted)]

2008, Volume 26, Issue 4

269-280 An Overview of Methods and Applications to Value Informal Care in Economic Evaluations of Healthcare
by Marc A. Koopmanschap & N. Job A. van Exel & Bernard van den Berg & Werner B.F. Brouwer [Downloadable! (restricted)]
281-296 Making a Case for Employing a Societal Perspective in the Evaluation of Medicaid Prescription Drug Interventions
by Sanjoy Roy & S. Suresh Madhavan [Downloadable! (restricted)]
297-310 The Use of QALY Weights for QALY Calculations: A Review of Industry Submissions Requesting Listing on the Australian Pharmaceutical Benefits Scheme 2002-4
by Paul A. Scuffham & Jennifer A. Whitty & Andrew Mitchell & Rosalie Viney [Downloadable! (restricted)]
311-328 Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis: Cost-Utility Analysis Using a Markov Model
by Simon Kreck & Jochen Klaus & Reiner Leidl & Christian von Tirpitz & Alexander Konnopka & Herbert Matschinger & Hans-Helmut Konig [Downloadable! (restricted)]
329-339 An Economic Evaluation of Atorvastatin for Primary Prevention of Cardiovascular Events in Type 2 Diabetes
by Scott D. Ramsey & Lauren D. Clarke & Craig S. Roberts & Sean D. Sullivan & Scott J. Johnson & Larry Z. Liu [Downloadable! (restricted)]
341-358 Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study
by Martin Knapp & Frank Windmeijer & Jacqueline Brown & Stathis Kontodimas & Spyridon Tzivelekis & Josep Maria Haro & Mark Ratcliffe & Jihyung Hong & Diego Novick [Downloadable! (restricted)]

2008, Volume 26, Issue 3

179-180 Meandering Down the Road to Transparency
by Christopher I. Carswell & Joseph A. Paladino [Downloadable! (restricted)]
181-183 Transparency of Economic Evaluations of Health Technologies
by Joan Rovira [Downloadable! (restricted)]
185-189 Projecting Vaccine Efficacy: Accounting for Geographic Strain Variations
by Johnie Rose & Mendel E. Singer [Downloadable! (restricted)]
191-215 Cost-Effectiveness Analyses of Vaccination Programmes: A Focused Review of Modelling Approaches
by Sun-Young Kim & Sue J. Goldie [Downloadable! (restricted)]
217-234 Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens
by Jeremy Chancellor & Samuel Aballea & Alison Lawrence & Rob Sheldon & Sandrine Cure & Juliette Plun-Favreau & Nick Marchant [Downloadable! (restricted)]
235-249 Community and Patient Values for Preventing Herpes Zoster
by Tracy A. Lieu & Ismael Ortega-Sanchez & G. Thomas Ray & Donna Rusinak & W. Katherine Yih & Peter W. Choo & Irene Shui & Ken Kleinman & Rafael Harpaz & Lisa A. Prosser [Downloadable! (restricted)]
251-268 Zoledronic Acid: A Pharmacoeconomic Review of its Use in the Management of Bone Metastases
by Kate McKeage & Greg L. Plosker [Downloadable! (restricted)]

2008, Volume 26, Issue 2

91-98 Having Your Cake and Eating It: Office of Fair Trading Proposal for Funding New Drugs to Benefit Patients and Innovative Companies
by Brian Godman & Alan Haycox & Ulrich Schwabe & Roberta Joppi & Silvio Garattini [Downloadable! (restricted)]
99-120 Management of Anaemia: A Critical and Systematic Review of the Cost Effectiveness of Erythropoiesis-Stimulating Agents
by Mei Sheng Duh & Jennifer R. Weiner & Leigh Ann White & Patrick Lefebvre & Paul E. Greenberg [Downloadable! (restricted)]
121-129 Economic Burden of Psoriatic Arthritis
by Christoph Ackermann & Arthur Kavanaugh [Downloadable! (restricted)]
131-148 Modelling Methods for Pharmacoeconomics and Health Technology Assessment: An Overview and Guide
by James E. Stahl [Downloadable! (restricted)]
149-162 The Burden of Schizophrenia on Caregivers: A Review
by A. George Awad & Lakshmi N.P. Voruganti [Downloadable! (restricted)]
163-178 Non-Traditional Settings for Influenza Vaccination of Adults: Costs and Cost Effectiveness
by Lisa A. Prosser & Megan A. O'Brien & Noelle-Angelique M. Molinari & Katherine H. Hohman & Kristin L. Nichol & Mark L. Messonnier & Tracy A. Lieu [Downloadable! (restricted)]

2008, Volume 26, Issue 1

1-4 The New Myth: The Social Value of the QALY
by Werner Brouwer & Job van Exel & Rachel Baker & Cam Donaldson [Downloadable! (restricted)]
5-15 The Last Decade of Italian Pharmaceutical Policy: Instability or Consolidation?
by Giovanni Fattore & Claudio Jommi [Downloadable! (restricted)]
17-32 Cost-Effectiveness Analyses of Hepatitis A Vaccine: A Systematic Review to Explore the Effect of Methodological Quality on the Economic Attractiveness of Vaccination Strategies
by Andrea M. Anonychuk & Andrea C. Tricco & Chris T. Bauch & Ba' Pham & Vladimir Gilca & Bernard Duval & Ava John-Baptiste & Gloria Woo & Murray Krahn [Downloadable! (restricted)]
33-44 Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas: A Cost-Utility Analysis
by Gabriel Rogers & Ruth Garside & Stuart Mealing & Martin Pitt & Rob Anderson & Matthew Dyer & Ken Stein & Margaret Somerville [Downloadable! (restricted)]
45-56 Dynamic Modelling of Infectious Diseases: An Application to the Economic Evaluation of Influenza Vaccination
by Roberto Pradas-Velasco & Fernando Antonanzas-Villar & Maria Puy Martinez-Zarate [Downloadable! (restricted)]
57-73 Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration: Multi-Country Observational Study
by Alan F. Cruess & Gergana Zlateva & Xiao Xu & Gisele Soubrane & Daniel Pauleikhoff & Andrew Lotery & Jordi Mones & Ronald Buggage & Caroline Schaefer & Tyler Knight & Thomas F. Goss [Downloadable! (restricted)]
75-90 Cost Effectiveness of Itraconazole in the Prophylaxis of Invasive Fungal Infections
by Robin de Vries & Simon Daenen & Keith Tolley & Axel Glasmacher & Archie Prentice & Sarah Howells & Hariette Christopherson & Lolkje T.W. de Jong-van den Berg & Maarten J. Postma [Downloadable! (restricted)]

2007, Volume 25, Issue 12

991-993 Acknowledgement
by Adis International Limited [Downloadable! (restricted)]
995-996 When NICE Says No!
by Alan Haycox [Downloadable! (restricted)]
997-1006 NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors: Was the Right Question Posed? Were the Best Tools Used?
by Denis Getsios & Kristen Migliaccio-Walle & Jaime J. Caro [Downloadable! (restricted)]
1007-1029 Recombinant Factor VIIa (Eptacog Alfa): A Pharmacoeconomic Review of its Use in Haemophilia in Patients with Inhibitors to Clotting Factors VIII or IX
by Katherine A. Lyseng-Williamson & Greg L. Plosker [Downloadable! (restricted)]
1031-1053 Atorvastatin: A Pharmacoeconomic Review of its Use in the Primary and Secondary Prevention of Cardiovascular Events
by Greg L. Plosker & Katherine A. Lyseng-Williamson [Downloadable! (restricted)]
1055-1062 Economic Evidence at the Local Level: Options for Making it More Useful
by Kees van Gool & Gisselle Gallego & Marion Haas & Rosalie Viney & Jane Hall & Robyn Ward [Downloadable! (restricted)]
1063-1082 Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events: An Assessment from the Payer's Perspective
by Bart Heeg & Joep Damen & Ben Van Hout [Downloadable! (restricted)]

2007, Volume 25, Issue 11

899-902 Warfarin Pharmacogenetics: Economic Considerations
by Dyfrig A. Hughes & Munir Pirmohamed [Downloadable! (restricted)]
903-911 It's Time to Choose the Study Design!: Net Benefit Analysis of Alternative Study Designs to Acquire Information for Evaluation of Health Technologies
by Oren Shavit & Moshe Leshno & Assaf Goldberger & Amir Shmueli & Amnon Hoffman [Downloadable! (restricted)]
913-933 The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A Structured Review of the Literature
by Rachael L. Fleurence & Cynthia P. Iglesias & Jeanene M. Johnson [Downloadable! (restricted)]
935-947 Economic Evaluations of Calcineurin Inhibitors in Renal Transplantation: A Literature Review
by Alec H. Miners & Guiqing Yao & James Raftery & Rod S. Taylor [Downloadable! (restricted)]
949-961 Strategies for the Management of Suspected Heparin-Induced Thrombocytopenia: A Cost-Effectiveness Analysis
by Amanda R. Patrick & Wolfgang C. Winkelmayer & Jerry Avorn & Michael A. Fischer [Downloadable! (restricted)]
963-977 Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B
by David L. Veenstra & Sean D. Sullivan & Lauren Clarke & Uche H. Iloeje & Eskinder Tafesse & Adrian Di Bisceglie & Kris V. Kowdley & Robert G. Gish [Downloadable! (restricted)]
979-990 The Economic Impact of Introducing Serotonin-Noradrenaline Reuptake Inhibitors into the Brazilian National Drug Formulary: Cost-Effectiveness and Budget-Impact Analyses
by Marcio Machado & Michael Iskedjian & Ines A. Ruiz & Thomas R. Einarson [Downloadable! (restricted)]

2007, Volume 25, Issue 10

807-816 Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions: Why Uncertainty About the Outcome, Estimate and Willingness to Pay Matters
by Jeffrey S. Hoch & Carolyn S. Dewa [Downloadable! (restricted)]
817-828 Valuing Children's Health: A Comparison of Cost-Utility Analyses for Adult and Paediatric Health Interventions in the US
by Joseph A. Ladapo & Peter J. Neumann & Ron Keren & Lisa A. Prosser [Downloadable! (restricted)]
829-841 A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD
by Laura Bojke & Edward Hornby & Mark Sculpher [Downloadable! (restricted)]
843-862 Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients
by Ya-Chen Tina Shih & Nebiyou B. Bekele & Ying Xu [Downloadable! (restricted)]
863-879 Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK
by Sorrel E. Wolowacz & Neil Roskell & Steven Kelly & Fiona M. Maciver & Chris S. Brand [Downloadable! (restricted)]
881-897 Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin: Economic Comparison in Adult and Adolescent Type 1 Diabetes Mellitus in Australia
by Neale Cohen & Michael E. Minshall & Lyn Sharon-Nash & Katerina Zakrzewska & William J. Valentine & Andrew J. Palmer [Downloadable! (restricted)]

2007, Volume 25, Issue 9

713-726 Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in Children: Theoretical and Methodological Considerations
by Lisa A. Prosser & James K. Hammitt & Ron Keren [Downloadable! (restricted)]
727-734 The Increasingly Complex Fourth Hurdle for Pharmaceuticals
by Joshua Cohen & Elly Stolk & Maartje Niezen [Downloadable! (restricted)]
735-750 Modelling Disease Progression in Alzheimer's Disease: A Review of Modelling Methods used for Cost-Effectiveness Analysis
by Colin Green [Downloadable! (restricted)]
751-768 Epidemiology and Economic Impact of Meticillin-Resistant Staphylococcus aureus: Review and Analysis of the Literature
by Andrew F. Shorr [Downloadable! (restricted)]
769-782 Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention
by Bart M.S. Heeg & Ron J.G. Peters & Marc Botteman & Ben A. van Hout [Downloadable! (restricted)]
783-792 Preferences of Community Pharmacists for Extended Roles in Primary Care: A Survey and Discrete Choice Experiment
by Anthony Scott & Christine Bond & Jackie Inch & Aileen Grant [Downloadable! (restricted)]
793-800 Reliability of Medicaid Claims Versus Medical Record Data: In a Cost Analysis of Palivizumab
by Julie Jacobson Vann & John Feaganes & Steven Wegner [Downloadable! (restricted)]
801-802 A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK
by Philip Home & Adrian Bagust & Matthew Taylor & Philip Ambery & Samara Mendes da Costa [Downloadable! (restricted)]
802-805 The Authors' Reply
by Dominic P. Tilden & Segundo Mariz & Gillies O'Bryan-Tear & Julia Bottomley & Alexander Diamantopoulos [Downloadable! (restricted)]

2007, Volume 25, Issue 8

621-635 When Drugs Don't Work: Economic Assessment of Enhancing Compliance with Interventions Supported by Electronic Monitoring Devices
by Dyfrig Hughes [Downloadable! (restricted)]
637-648 Impact of Pharmaceutical Prior Authorisation Policies: A Systematic Review of the Literature
by Jaume Puig-Junoy & Ivan Moreno-Torres [Downloadable! (restricted)]
649-664 The Contrast and Convergence of Bayesian and Frequentist Statistical Approaches in Pharmacoeconomic Analysis
by Grant H. Skrepnek [Downloadable! (restricted)]
665-676 Healthcare Utilisation and Costs Associated with Adding Montelukast to Current Therapy in Patients with Mild to Moderate Asthma and Co-Morbid Allergic Rhinitis: PRAACTICAL Study
by Roberto Dal Negro & Peter Piskorz & Roberto Vives & Magda Guilera & Vasilisa Sazonov Kocevar & Xavier Badia [Downloadable! (restricted)]
677-683 Direct Costs in Patients Hospitalised with Community-Acquired Pneumonia After Non-Response to Outpatient Treatment with Macrolide Antibacterials in the US
by Joseph A. Paladino & Martin H. Adelman & Jerome J. Schentag & Paul B. Iannini [Downloadable! (restricted)]
685-693 A Stated Preference Binary Choice Experiment to Explore NICE Decision Making
by Paul Tappenden & John Brazier & Julie Ratcliffe & James Chilcott [Downloadable! (restricted)]
695-711 A 1-Year Prospective Cost-Effectiveness Analysis of Roflumilast for the Treatment of Patients with Severe Chronic Obstructive Pulmonary Disease
by Maureen P.M.H. Rutten-van Molken & Floortje E. van Nooten & Marion Lindemann & Manfred Caeser & Peter M.A. Calverley [Downloadable! (restricted)]

2007, Volume 25, Issue 7

533-535 Perspectives on Dynamic Optimisation and Control Theory in Treating Hyperlipidaemia
by John A. Vernon [Downloadable! (restricted)]
537-562 Cost Considerations in the Treatment of Colorectal Cancer
by Frank G.A. Jansman & Maarten J. Postma & Jacobus R.B.J. Brouwers [Downloadable! (restricted)]
563-576 Retrospective Economic and Outcomes Analyses Using Non-US Databases: A Review
by Lizheng Shi & Eric Q Wu & Meredith Hodges & Andrew Yu & Howard Birnbaum [Downloadable! (restricted)]
577-590 A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma
by Ya-Chen Tina Shih & Josephine Mauskopf & Rohit Borker [Downloadable! (restricted)]
591-603 The Use of Disease-Specific Outcome Measures in Cost-Utility Analysis: The Development of Dutch Societal Preference Weights for the FACT-L Scale
by Leida M. Lamers & Carin A. Uyl-de Groot & Ivonne Buijt [Downloadable! (restricted)]
605-618 Direct and Indirect Costs Attributable to Alcohol Consumption in Germany
by Alexander Konnopka & Hans-Helmut Konig [Downloadable! (restricted)]
619 Cost-Utility Analysis in China: Differences and Difficulties Compared with Developed Countries
by Liu Bao Peng & Chong Qing Tan & Xiao Min Wan & Wei Cui [Downloadable! (restricted)]

2007, Volume 25, Issue 6

443-454 Reform of Prescription Drug Reimbursement and Pricing in the German Social Health Insurance Market: A Comparison of Three Scenarios
by Stefan Gress & Dea Niebuhr & Uwe May & Jurgen Wasem [Downloadable! (restricted)]
455-466 Estimation, Power and Sample Size Calculations for Stochastic Cost and Effectiveness Analysis
by S.D. Walter & Amiram Gafni & Stephen Birch [Downloadable! (restricted)]
467-479 A Systematic Review of Economic Evaluation Literature in Thailand: Are the Data Good Enough to be Used by Policy-Makers?
by Yot Teerawattananon & Steve Russell & Miranda Mugford [Downloadable! (restricted)]
481-496 Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs: A Retrospective Analysis among Managed Care Patients with Chronic Myelogenous Leukaemia
by Theodore Darkow & Henry J. Henk & Simu K. Thomas & Weiwei Feng & Jean-Francois Baladi & George A. Goldberg & Alan Hatfield & Jorge Cortes [Downloadable! (restricted)]
497-509 Cost Effectiveness of Oseltamivir Treatment for Patients with Influenza-Like Illness Who Are at Increased Risk for Serious Complications of Influenza: Illustration for The Netherlands
by Maarten J. Postma & Annoesjka Novak & Huib W.K.F.H. Scheijbeler & Marlene Gyldmark & Marianne L.L. van Genugten & Jan C. Wilschut [Downloadable! (restricted)]
511-521 Costs and Benefits of Direct-to-Consumer Advertising: The Case of Depression
by Adam E. Block [Downloadable! (restricted)]
523-528 Building Bridges Between Academic Research and Policy Formulation: When Costing Less Means Costing More
by Amiram Gafni & Stephen Birch [Downloadable! (restricted)]
528-532 Being Led Down the Wrong Garden PATH: the Importance of Knowledge and Facts for the Crossroads
by Ron Goeree & Daria O'Reilly & Jean-Eric Tarride & Jim Bowen & Gord Blackhouse & Kaitryn Campbell & Rob Hopkins & Morgan Lim & Lisa Patterson [Downloadable! (restricted)]

2007, Volume 25, Issue 5

355-363 Replace Pharmaceutical Patents Now
by Earl L. Grinols & James W. Henderson [Downloadable! (restricted)]
365-384 Health Utilities Using the EQ-5D in Studies of Cancer
by A. Simon Pickard & Caitlyn T. Wilke & Hsiang-Wen Lin & Andrew Lloyd [Downloadable! (restricted)]
385-396 The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD): Responsiveness to Change and English Language Validation
by Peter Wahlqvist & Gordon H. Guyatt & David Armstrong & Alessio Degl'Innocenti & Diane Heels-Ansdell & Samer El-Dika & Ingela Wiklund & Carlo A. Fallone & Lisa Tanser & Sander Veldhuyzen van Zanten & Peggy Austin & Alan N. Barkun & Naoki Chiba & Holger J. Schunemann [Downloadable! (restricted)]
397-411 Costs of a Community Pharmacist-Led Medicines Management Service for Patients with Coronary Heart Disease in England: Healthcare System and Patient Perspectives
by Anthony Scott & Michela Tinelli & Christine Bond [Downloadable! (restricted)]
413-428 Economic Evaluation of Treatment Administration Strategies of Ganciclovir for Cytomegalovirus Retinitis in HIV/AIDS Patients in Thailand: A Simulation Study
by Kanlaya Teerawattananon & Saniorn Iewsakul & Chawewan Yenjitr & Somsanguan Ausayakhun & Watanee Yenjitr & Miranda Mugford & Yot Teerawattananon [Downloadable! (restricted)]
429-442 Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer: A Lifetime Model
by J. Alasdair Millar & Michael J. Millward [Downloadable! (restricted)]

2007, Volume 25, Issue 4

267-268 Letter From the Commissioner's Office at the US FDA
by John A. Vernon [Downloadable! (restricted)]
269-286 Measuring Patient-Reported Outcomes in Solid Organ Transplant Recipients: An Overview of Instruments Developed to Date
by Irina Cleemput & Fabienne Dobbels [Downloadable! (restricted)]
287-308 The Economic Implications of Glaucoma: A Literature Review
by Jordana K. Schmier & Michael T. Halpern & Mechelle L. Jones [Downloadable! (restricted)]
309-327 Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer
by Steven B. Zeliadt & David F. Penson [Downloadable! (restricted)]
329-342 Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients: US Healthcare System Perspective
by Thomas E. Delea & Oleg Sofrygin & Simu K. Thomas & Jean-Francois Baladi & Pradyumna D. Phatak & Thomas D. Coates [Downloadable! (restricted)]
343-351 Therapeutic Use of Granulocyte Colony-Stimulating Factors for Established Febrile Neutropenia: Effect on Costs from a Hospital Perspective
by Leon E. Cosler & Adi Eldar-Lissai & Eva Culakova & Nicole M. Kuderer & David Dale & Jeffrey Crawford & Gary H. Lyman [Downloadable! (restricted)]
353 Book Review
by Adis International Limited [Downloadable! (restricted)]

2007, Volume 25, Issue 3

181-185 Economic Evaluation and Decision Making: Reimbursing Trastuzumab in Early-Stage Breast Cancer
by Steven Simoens [Downloadable! (restricted)]
187-199 Economic Evaluations of Cholesterol-Lowering Drugs: A Critical and Systematic Review
by Pearl D. Gumbs & Monique W.M. Verschuren & Aukje K. Mantel-Teeuwisse & Ardine G. de Wit & Anthonius de Boer & Olaf H. Klungel [Downloadable! (restricted)]
201-208 Enzyme Replacement Therapy in Orphan and Ultra-Orphan Diseases: The Limitations of Standard Economic Metrics as Exemplified by Fabry-Anderson Disease
by David F. Moore & Markus Ries & Evelyn L. Forget & Raphael Schiffmann [Downloadable! (restricted)]
209-221 Do Drugs Reduce Utilisation of Other Healthcare Resources?
by Pierre-Yves Cremieux & Pierre Ouellette & Patrick Petit [Downloadable! (restricted)]
223-237 Recombinant Erythropoietin for Chemotherapy-Related Anaemia: Economic Value and Health-Related Quality-of-Life Assessment Using Direct Utility Elicitation and Discrete Choice Experiment Methods
by Diego F. Ossa & Andrew Briggs & Emma McIntosh & Warren Cowell & Tim Littlewood & Mark Sculpher [Downloadable! (restricted)]
239-251 Cost Effectiveness of an Adherence-Improving Programme in Hypertensive Patients
by Danielle E.M. Brunenberg & Gwenn E.C. Wetzels & Patricia J. Nelemans & Carmen D. Dirksen & Johan L. Severens & Henri E.J.H. Stoffers & Jan S.A.G. Schouten & Martin H. Prins & Peter W. de Leeuw & Manuela A. Joore [Downloadable! (restricted)]
253-266 Modelling Cost Effectiveness of Insulin Glargine for the Treatment of Type 1 and 2 Diabetes in Canada
by Daniel T. Grima & Melissa F. Thompson & Luc Sauriol [Downloadable! (restricted)]

2007, Volume 25, Issue 2

89-90 Letter From the Commissioner's Office at the US FDA
by John A. Vernon [Downloadable! (restricted)]
91-92 Is Medication Review by Pharmacists of Any Use?
by Arnold G. Zermansky & Nick Freemantle [Downloadable! (restricted)]
93-106 Measuring Preferences for Cost-Utility Analysis: How Choice of Method May Influence Decision-Making
by Christine M. McDonough & Anna N.A. Tosteson [Downloadable! (restricted)]
107-127 A `League Table' of Contingent Valuation Results for Pharmaceutical Interventions: A Hard Pill to Swallow?
by Tracey H. Sach & Richard D. Smith & David K. Whynes [Downloadable! (restricted)]
129-142 Disease Burden of Overactive Bladder: Quality-of-Life Data Assessed Using ICI-Recommended Instruments
by Ramandeep Basra & Con Kelleher [Downloadable! (restricted)]
143-154 Conjoint Analysis of French and German Parents' Willingness to Pay for Meningococcal Vaccine
by David Bishai & Roger Brice & Isabelle Girod & Aneta Saleh & Jenifer Ehreth [Downloadable! (restricted)]
155-169 Acute/Subacute Herpes Zoster: Healthcare Resource Utilisation and Costs in a Group of US Health Plans
by Ralph P. Insinga & Robbin F. Itzler & James M. Pellissier [Downloadable! (restricted)]
171-180 Home-Based Medication Review in Older People: Is it Cost Effective?
by Margaret Pacini & Richard D. Smith & Edward C.F. Wilson & Richard Holland [Downloadable! (restricted)]

2007, Volume 25, Issue 1

1-2 Letter From the Commissioner's Office at the US FDA
by John A. Vernon [Downloadable! (restricted)]
3-6 Rates and Probabilities in Economic Modelling: Transformation, Translation and Appropriate Application
by Rachael L. Fleurence & Christopher S. Hollenbeak [Downloadable! (restricted)]
7-24 Reducing the Societal Burden of Depression: A Review of Economic Costs, Quality of Care and Effects of Treatment
by Julie M. Donohue & Harold Alan Pincus [Downloadable! (restricted)]
25-37 Cost Effectiveness of a Pharmacy-Based Coaching Programme to Improve Adherence to Antidepressants
by Judith E. Bosmans & Oscar H. Brook & Hein P.J. van Hout & Martine C. de Bruijne & Hugo Nieuwenhuyse & Lex M. Bouter & Wim A.B. Stalman & Maurits W. van Tulder [Downloadable! (restricted)]
39-54 A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK
by Dominic P. Tilden & Segundo Mariz & Gillies O'Bryan-Tear & Julia Bottomley & Alexander Diamantopoulos [Downloadable! (restricted)]
55-71 Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis
by Mark J.C. Nuijten & Wolfgang Wittenberg & Maximilian Lebmeier [Downloadable! (restricted)]
73-88 Time Preferences for Health in Northern Tanzania: An Empirical Analysis of Alternative Discounting Models
by Bjarne Robberstad & John Cairns [Downloadable! (restricted)]

2006, Volume 24, Issue 12

1169-1171 Acknowledgement
by Adis International Limited [Downloadable! (restricted)]
1173-1177 Do Pharmacogenomic Tests Provide Value to Policy Makers?
by Ya-Chen Tina Shih & Lajos Pusztai [Downloadable! (restricted)]
1179 Letter From the Commissioner's Office at the US FDA
by John A. Vernon [Downloadable! (restricted)]
1181-1197 Assessing Generalisability in Model-Based Economic Evaluation Studies: A Structured Review in Osteoporosis
by Hege Urdahl & Andrea Manca & Mark J. Sculpher [Downloadable! (restricted)]
1199-1220 Generic Health-Related Quality-of-Life Assessment in Children and Adolescents: Methodological Considerations
by Ulrike Ravens-Sieberer & Michael Erhart & Nora Wille & Ralf Wetzel & Jennifer Nickel & Monika Bullinger [Downloadable! (restricted)]
1221-1232 Cost Effectiveness of Tumour Necrosis Factor-alpha Inhibitors as First-Line Agents in Rheumatoid Arthritis
by James R. Spalding & Joel Hay [Downloadable! (restricted)]
1233-1248 Association of Co-Morbidities with Prescribing Patterns and Cost Savings: Olanzapine versus Risperidone for Schizophrenia
by Wei Yu & Xinhua S. Ren & Austin F. Lee & Lawrence Herz & Yu-Hui Huang & Lewis E. Kazis [Downloadable! (restricted)]
1249-1272 Candesartan Cilexetil: A Pharmacoeconomic Review of its Use in Chronic Heart Failure and Hypertension
by Greg L. Plosker & Susan J. Keam [Downloadable! (restricted)]
1273-1274 Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies
by Stuart Birks [Downloadable! (restricted)]
1275-1276 The Authors' Reply
by J.M. Bos & M.J. Postma & L. Annemans [Downloadable! (restricted)]

2006, Volume 24, Issue 11

1039-1042 Better Analysis for Better Decisions: Facing Up to the Challenges
by Michael F. Drummond & Mark J. Sculpher [Downloadable! (restricted)]
1043-1053 Recent Developments in Decision-Analytic Modelling for Economic Evaluation
by Milton C. Weinstein [Downloadable! (restricted)]
1055-1068 Using Value of Information Analysis to Prioritise Health Research: Some Lessons from Recent UK Experience
by Karl P. Claxton & Mark J. Sculpher [Downloadable! (restricted)]
1069-1078 Utility Measurement in Healthcare: The Things I Never Got To
by George W. Torrance [Downloadable! (restricted)]
1079-1086 Pharmacoeconomics and Pharmacoepidemiology: Curious Bedfellows or a Match Made in Heaven?
by Andrew H. Briggs & Adrian R. Levy [Downloadable! (restricted)]
1087-1099 Analysis Sans Frontieres: Can We Ever Make Economic Evaluations Generalisable Across Jurisdictions?
by Mark J. Sculpher & Michael F. Drummond [Downloadable! (restricted)]
1101-1119 `Lost in Translation': Accounting for Between-Country Differences in the Analysis of Multinational Cost-Effectiveness Data
by Andrea Manca & Andrew R. Willan [Downloadable! (restricted)]
1121-1131 Information Created to Evade Reality (ICER): Things We Should Not Look to for Answers
by Stephen Birch & Amiram Gafni [Downloadable! (restricted)]
1133-1142 Economic Evaluation and Decision Making in the UK
by Martin J. Buxton [Downloadable! (restricted)]
1143-1156 Building Bridges Between Academic Research and Policy Formulation: The PRUFE Framework - an Integral Part of Ontario's Evidence-Based HTPA Process
by Ron Goeree & Leslie Levin [Downloadable! (restricted)]
1157-1162 Economic Evaluations in the Canadian Common Drug Review
by Andreas Laupacis [Downloadable! (restricted)]
1163-1168 Economic Evaluation in the US: What is the Missing Link?
by Peter J. Neumann & Sean D. Sullivan [Downloadable! (restricted)]

2006, Volume 24, Issue 10

937-945 The Generalisability of Pharmacoeconomic Studies: Issues and Challenges Ahead
by James M. Mason & Anne R. Mason [Downloadable! (restricted)]
947-952 QALYs: Are They Helpful to Decision Makers?
by Maurice McGregor & J. Jaime Caro [Downloadable! (restricted)]
953-954 Should We Abandon QALYs as a Resource Allocation Tool?
by Sandeep Vijan [Downloadable! (restricted)]
955-970 Therapeutic Options for the Prevention and Treatment of Postoperative Nausea and Vomiting: A Pharmacoeconomic Review
by Jean Lachaine [Downloadable! (restricted)]
971-988 Single-Inhaler Combination Therapy for Asthma: A Review of Cost Effectiveness
by Manabu Akazawa & David A. Stempel [Downloadable! (restricted)]
989-998 Disability and Quality of Life in Post-Traumatic Stress Disorder: Impact of Drug Treatment
by Soraya Seedat & Christine Lochner & Bavanisha Vythilingum & Dan J. Stein [Downloadable! (restricted)]
999-1009 Hospitalisation Costs of Cystic Fibrosis
by Jonas Schreyogg & Helge Hollmeyer & Miriam Bluemel & Doris Staab & Reinhard Busse [Downloadable! (restricted)]
1011-1020 The Initial Validation of a Markov Model for the Economic Evaluation of (New) Treatments for Rheumatoid Arthritis
by Paco M.J. Welsing & Johan L. Severens & Margriet Hartman & Anke M. van Gestel & Piet L.C.M. van Riel & Roland F.J.M. Laan [Downloadable! (restricted)]
1021-1033 The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the US
by Patrick W. Sullivan & Thomas W. Arant & Samuel L. Ellis & Heather Ulrich [Downloadable! (restricted)]
1035-1038 Anticoagulation for Stroke Prevention: High Effectiveness, More Cost Benefit?
by Eduard Shantsila & Timothy Watson & Gregory Y.H. Lip [Downloadable! (restricted)]

2006, Volume 24, Issue 9

833-836 US FDA Guidance: Apropos of PROs
by Paul Kind [Downloadable! (restricted)]
837-844 Accuracy versus Transparency in Pharmacoeconomic Modelling: Finding the Right Balance
by David M. Eddy [Downloadable! (restricted)]
845-853 The Value of Thinly Spread QALYs
by Duncan Mortimer [Downloadable! (restricted)]
855-868 Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework: Some Considerations
by Emma McIntosh [Downloadable! (restricted)]
869-890 Cost-of-Illness Studies: A Review of Current Methods
by Ebere Akobundu & Jing Ju & Lisa Blatt & C. Daniel Mullins [Downloadable! (restricted)]
891-902 Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996-2003
by Yue-Chune Lee & Ming-Chin Yang & Yu-Tung Huang & Chien-Hsiang Liu & Sun-Bing Chen [Downloadable! (restricted)]
903-915 Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia: Cost Effectiveness and Risk Sharing
by John H. Wlodarczyk & Leslie G. Cleland & Anne M. Keogh & Keith D. McNeil & Kate Perl & Robert G. Weintraub & Trevor J. Williams [Downloadable! (restricted)]
917-925 Missing Data Imputation in Quality-of-Life Assessment: Imputation for WHOQOL-BREF
by Ting Hsiang Lin [Downloadable! (restricted)]
927-929 Modelling Lifetime Metabolic Progression and Cost Effectiveness of Treatment Strategies for Type 2 Diabetes
by Andrew J. Palmer & Craig J. Currie [Downloadable! (restricted)]
929-935 The Authors' Reply
by Adrian A. Bagust & Marc Evans & Sophie Beale & Philip Home & Andrew Perry & Murray Stewart & Arran Shearer & Alan Martin & Lisa Hulme & Andreas Liebl & Oliver Schoeffski & Anita Goertz & Javier Ampudia-Blasco & Belen Martinez-Lage & Isabel Perez Escolano & Gonzalo Paris [Downloadable! (restricted)]

2006, Volume 24, Issue 8

727-742 Cost Effectiveness of Leukotriene Modifiers in Adults with Asthma
by Pamela C. Heaton [Downloadable! (restricted)]
743-750 Prostaglandin Analogues for the Treatment of Glaucoma and Ocular Hypertension: A Systematic Review of Economic Evidence
by Michelle Orme & Annabel Boler [Downloadable! (restricted)]

More pages of listings: 0|1|2|3|4|5

Access and download statistics

Did you know? You too can volunteer for RePEc, for example by encouraging others to register as authors.

This page was last updated on 2008-9-24.

This information is provided to you by IDEAS at the Department of Economics, College of Liberal Arts and Sciences, University of Connecticut using RePEc data on a server sponsored by the Society for Economic Dynamics.